產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時服務(wù)熱線
NCI-H295R (人腎上腺皮質(zhì)腺癌細胞) (STR鑒定正確)
貨號:CL-0399
規(guī)格:1×10?cells/T25培養(yǎng)瓶
價格: ¥1600
生長培養(yǎng)基:DMEM/F12+0.5% ITS-G(100×)+10% FBS+1% P/S
產(chǎn)品概述
名稱 | NCI-H295R (人腎上腺皮質(zhì)腺癌細胞) (STR鑒定正確) |
別稱 | NCI H295R; NCIH295R; H295R; H-295R; H295R-S1 |
種屬 | 人 |
生長特性 | 貼壁細胞 |
細胞形態(tài) | 上皮細胞樣 |
凍存條件 | 凍存液:55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度:液氮 |
培養(yǎng)方案A(默認) |
生長培養(yǎng)基:
培養(yǎng)條件:
氣相:空氣,95%;CO2,5%, 溫度:37℃
|
推薦傳代比例 | 1:2-1:4 |
推薦換液頻率 | 2-3次/周 |
背景描述 | NCI-H295R細胞是源于多能腎上腺皮質(zhì)癌細胞系NCI-H295細胞,后者由Gazdar·A·F等建立,從腎上腺皮質(zhì)的腫瘤中分離而來。NCI-H295細胞經(jīng)改變培養(yǎng)條件獲得了NCI-295R細胞,群體倍增時間從原來的5天減為2天。NCI-295細胞懸浮生長,而NCI-H295R細胞呈單層貼壁生長。NCI-H295R細胞保留了產(chǎn)生雄激素的能力,對血管緊張素Ⅱ和鉀離子有反應(yīng)。 |
年齡(性別) | 女性;48歲 |
組織來源 | 器官:腎上腺 |
細胞類型 | 腫瘤細胞 |
腫瘤類型 | 腎上腺皮質(zhì)癌細胞 |
生物安全等級 | BSL-1 |
基因表達情況 | aldosterone; cortisol; C19 steroids |
保藏機構(gòu) | ATCC; CRL-2128 |
STR鑒定
-
STR位點信息
Amelogenin X CSF1PO 10,12 D2S1338 25 D3S1358 15,16 D5S818 12 D7S820 9,12 D8S1179 13 D13S317 13 D16S539 11 D18S51 17 D19S433 13 D21S11 32.2 FGA 19.2,24 PentaD 8 PentaE 5,12 TH01 9.3 TPOX 8 vWA 17,18 D6S1043 11 D12S391 19,20 D2S441 11 -
STR鑒定圖
-
參考文獻
-
β-Elemene Inhibits Adrenocortical Carcinoma Cell Proliferation and Migration, and Induces Apoptosis by Up-Regulating miR-486-3p/Targeting NPTX1 Axis (2025-01-13)
期刊:MOLECULAR CARCINOGENESIS
DOI:10.1002/mc.23879
影響因子 :3.0
引用產(chǎn)品: SW-13 細胞 , NCI-H295R 細胞 , 293T [HEK-293T] 細胞
-
LncRNA ZFHX4-AS1 as a novel biomarker in adrenocortical carcinoma (2024-07-16)
期刊:Translational Andrology and Urology
影響因子 :1.9
引用產(chǎn)品: SW-13 細胞 , NCI-H295R 細胞
-
Sinapine Targeting PLCβ3 EF Hands Disrupts Gαq-PLCβ3 Interaction and Ameliorates Cardiovascular Diseases (2023-11-15)
期刊:PHYTOMEDICINE
DOI:10.1016/j.phymed.2023.155200
影響因子 :7.9
引用產(chǎn)品: NCI-H295R 細胞 , H9c2 (2-1) 細胞 , A7r5 細胞
-
Spatial lipidomics and metabolomics of multicellular tumor spheroids using MALDI-2 and trapped ion mobility imaging (2023-06-20)
期刊:TALANTA
DOI:10.1016/j.talanta.2023.124795
影響因子 :6.1
引用產(chǎn)品: NCI-H295R 細胞
-
N7-methylguanosine regulatory genes well represented by METTL1 define vastly different prognostic, immune and therapy landscapes in adrenocortical carcinoma (2023-02-15)
期刊:American Journal of Cancer Research
DOI:PMID:36895966
影響因子 :5.3
引用產(chǎn)品: NCI-H295R 細胞 , SW-13 細胞
-
KIF11 is a potential prognostic biomarker and therapeutic target for adrenocortical carcinoma (2023-03-20)
期刊:Translational Andrology and Urology
影響因子 :2.0
引用產(chǎn)品: NCI-H295R 細胞 , DMEM高糖 培養(yǎng)基
-
CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis (2022-10-02)
期刊:Journal of Translational Medicine
DOI:10.1186/s12967-022-03641-y
影響因子 :8.4
引用產(chǎn)品: NCI-H295R 細胞 , SW-13 細胞 , SW-13細胞專用培養(yǎng)基 (L15) , NCI-H295R細胞專用培養(yǎng)基
-
Combining virtual screening and in vitro evaluation for the discovery of potential CYP11B2 inhibitors (2022-08-01)
期刊:Future Medicinal Chemistry
影響因子 :4.8
引用產(chǎn)品: NCTC clone 929 [L 細胞, L-929] 細胞 , NCI-H295R 細胞
-
IFNγ enhances ferroptosis by increasing JAK?STAT pathway activation to suppress SLCA711 expression in adrenocortical carcinoma (2022-03-23)
期刊:Oncology Reports
影響因子 :4.2
引用產(chǎn)品: NCI-H295R 細胞 , NCI-H295R細胞專用培養(yǎng)基
-
Identification of Seven Aberrantly Methylated and Expressed Genes in Adrenocortical Carcinoma (2019-07-12)
期刊:Frontiers in Endocrinology
影響因子 :5.2
引用產(chǎn)品: SW-13 細胞 , NCI-H295R 細胞
FAQs
Q:{{item.question}}
A:
產(chǎn)品資料


識別碼示意圖